ImmuCell Corporation (ICCC) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for ImmuCell Corporation (ICCC:NASDAQ), powered by AI.

Current Price
$9.38
Sector
Healthcare
What is the ImmuCell Corporation stock price forecast?

ImmuCell Corporation is currently trading at $9.38. View real-time AI analysis on Alpha Lenz.

What is ImmuCell Corporation insider trading activity?

View the latest insider trading data for ImmuCell Corporation on Alpha Lenz.

What is ImmuCell Corporation's P/E ratio?

View ImmuCell Corporation's valuation metrics on Alpha Lenz.

ImmuCell Corporation

NASDAQ · ICCC
$9.38-0.15(-1.57%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about ImmuCell Corporation's future dividend policy...
Alpha Chat Insight

ImmuCell Corporation's ROE is -3.8%. Explore profitability and growth together.

Ask for details

Company Overview

ImmuCell Corporation is a biotechnology company engaged in the development, manufacture, and sale of products that improve animal health and productivity in the dairy and beef industries. The company's primary focus is on the development of products that provide alternatives to traditional antibiotics, offering innovative solutions to enhance the immune system of livestock. ImmuCell’s notable product, First Defense, helps prevent scours (diarrhea) in newborn dairy and beef calves, a common ailment that can impair growth and development and lead to high mortality rates. By addressing such pervasive health challenges in the livestock sector, ImmuCell significantly impacts agricultural productivity and sustainability. Located in the United States, ImmuCell Corporation contributes to the broader biotechnology and agricultural markets by promoting healthier livestock, thereby potentially reducing the dependency on antibiotics and aligning with global trends towards more sustainable and responsible farming practices. This focus not only underscores the company’s role in animal health innovation but also highlights its importance in food safety and the agricultural supply chain.

CEOMr. Michael F. Brigham
SectorHealthcare
IndustryBiotechnology
Employees69

Company Statistics

FY 2025

Profile

N/AMarket Cap
$27.64MRevenue
0.00Shares Out
69Employees

Margins

41.40%Gross
16.23%EBITDA
5.97%Operating
-3.72%Pre-Tax
-3.76%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

14.19%Rev 3Yr
12.50%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-2.37%ROA
-3.81%ROE
-1.35%ROIC

Financial Health

$3.81MCash & Cash Equivalents
$11.67MNet Debt
57.20%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

ImmuCell Corporation (ticker: ICCC) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 69 employees.

The current price is $9.38 with a P/E ratio of -x and P/B of -x.

ROE is -3.81% and operating margin is 5.97%. Annual revenue is $28M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
ImmuCell Corporation (ICCC) Stock Forecast 2026 $9.38 — Price, Financials & Analyst Targets | Alpha Lenz